Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | RMC-6291 |
| Synonyms | |
| Therapy Description |
RMC-6291 is a small molecule that selectively inhibits active KRAS G12C by forming a tri-complex with KRAS G12C and cyclophilin A, potentially resulting in decreased RAS signaling and tumor cell proliferation, and reduced tumor growth (PMID: 37590355). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| RMC-6291 | RMC6291RM032|RM-032|RMC 6291 | KRAS G12C inhibitor 36 | RMC-6291 is a small molecule that selectively inhibits active KRAS G12C by forming a tri-complex with KRAS G12C and cyclophilin A, potentially resulting in decreased RAS signaling and tumor cell proliferation, and reduced tumor growth (PMID: 37590355). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05462717 | Phase I | RMC-6291 | Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | Active, not recruiting | USA | POL | ITA | FRA | ESP | CZE | AUS | 6 |